Vein of Marshall Ethanol Ablation as a Strategy for Recurrent Persistent Atrial Fibrillation
Journal of Cardiovascular Electrophysiology · 2025
DOI: 10.1111/jce.70114 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cardiovascular Electrophysiology, 2025. Verfasst von Brian C Hsia und 14 weiteren Autor:innen. Beteiligte Einrichtung: Leon H. Charney Division of Cardiology, New York University Langone Health, New York City, New York, USA. Hauptthemen laut MEDLINE: Atrial Fibrillation, Ethanol, Pulmonary Veins, Ablation Techniques. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 33 Literaturangaben. Gefördert von: The authors received no specific funding for this work..
Abstract (Originalsprache)
Background
Vein of Marshall (VOM) ethanol ablation is effective in preventing recurrence in patients with persistent atrial fibrillation (AF) as a de novo strategy. There is minimal data on its use in recurrent AF.
Objective
We investigated the efficacy of VOM ethanol ablation for recurrence despite initial AF ablation.
Methods
Retrospective analysis was performed of persistent AF patients who underwent repeat ablation after an initial ablation for persistent AF. All patients had pulmonary vein isolation (PVI), posterior wall isolation (PWI), and cavotricuspid isthmus (CTI) during their previous ablation(s). At redo ablation, controls underwent confirmation and completion of previous ablation steps, substrate modification, and a search for non‐PV triggers. Cases had additional VOM ethanol ablation combined with mitral isthmus ablation.
Results
One hundred and seven patients (49 VOM, 60 control) were included. There was no difference in AF recurrence at 1‐year comparing VOM patients (47%) and controls (38%), ( p = 0.39). Within the VOM group, the mean AF burden decreased from 38% preablation to 10% 12‐months post ( p = 0.003). The proportion of recurrent persistent AF decreased from 65% preablation to 26% post ( p = 0.004). There was no significant difference in reduction in AF burden or proportion of recurrent persistent AF when comparing VOM cases and controls. Six percent of VOM patients developed intraprocedural left atrial appendage (LAA) isolation.
Conclusions
In patients with previous PVI, PWI, and CTI ablation, VOM ethanol ablation did not demonstrate a reduction in AF recurrence or burden when compared with a strategy of substrate modification and trigger ablation alone and increases the risk of LAA isolation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Leon H. Charney Division of Cardiology, New York University Langone Health, New York City, New York, USA.
- Department of Internal Medicine, New York University Langone Health, New York City, New York, USA.
ORCID-Profile: Brian C Hsia, Larry A Chinitz, Anthony Aizer
Förderung
- The authors received no specific funding for this work.
Zitieren
APA
Hsia, B. C., Zhang, P., Junarta, J., Garber, L., Yang, F., Spinelli, M., Malyshev, Y., Kushnir, A., Jankelson, L., Bernstein, S., Park, D., Barbhaiya, C., Holmes, D., Chinitz, L. A., & Aizer, A. (2025). Vein of Marshall Ethanol Ablation as a Strategy for Recurrent Persistent Atrial Fibrillation. Journal of Cardiovascular Electrophysiology. https://doi.org/10.1111/jce.70114
Vancouver
Hsia BC, Zhang P, Junarta J, Garber L, Yang F, Spinelli M, et al. Vein of Marshall Ethanol Ablation as a Strategy for Recurrent Persistent Atrial Fibrillation. Journal of Cardiovascular Electrophysiology. 2025. doi:10.1111/jce.70114
BibTeX
@article{Hsia2025,
author = {Hsia, Brian C and Zhang, Peter and Junarta, Joey and Garber, Leonid and Yang, Felix and Spinelli, Michael and Malyshev, Yury and Kushnir, Alexander and Jankelson, Lior and Bernstein, Scott and Park, David and Barbhaiya, Chirag and Holmes, Douglas and Chinitz, Larry A and Aizer, Anthony},
title = {Vein of Marshall Ethanol Ablation as a Strategy for Recurrent Persistent Atrial Fibrillation},
journal = {Journal of Cardiovascular Electrophysiology},
year = {2025},
doi = {10.1111/jce.70114}
}
EUVIMED